Close menu

April 19th, 2023 | 11:20 CEST

BioNxt Solutions, Bayer, Morphosys - Using high-speed technology to beat cancer in men

  • Biotechnology
  • Pharma
  • Cancer
Photo credits: Bayer Healthcare

Cancer drugs dominate the global pharmaceutical market and register a significant share. While the global market was worth around EUR 128.6 billion in 2019, it is expected to be around EUR 159.3 billion in 2022. This is reason enough for pharmaceutical companies such as Bayer and Morphosys to advance their research in these areas. Men are particularly affected by specific types of cancer. But what good is the best therapeutic agent if the effect is not achieved immediately? This is precisely where BioNxt Solutions comes in, with a unique coating technology for the rapid release of active substances.

time to read: 4 minutes | Author: Juliane Zielonka
ISIN: Bionxt Solutions Inc. | CA0909741062 , BAYER AG NA O.N. | DE000BAY0017 , MORPHOSYS AG O.N. | DE0006632003

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    BioNxt Solutions - Novel coating ensures rapid release of active ingredient

    Anyone who has ever been unwell knows that moment when, after taking a medicine, the effect unfolds in the body, and the active ingredient does its work.

    **This is where BioNxt comes in, with a novel coating technology for orally administered drugs and active ingredients. The faster the active ingredient of an orally administered drug unfolds its effect, the faster patients feel relief from their symptoms. A so-called coating technology is responsible for the commercial implementation. Particularly exciting for investors: this technology can be patented.

    "With BioNxt already having established platforms for transdermal and oral soluble drug delivery, this acquisition of a novel coating technology for oral drugs is a significant step in expanding and consolidating our drug delivery expertise," said Hugh Rogers, CEO & Director of BioNxt.

    The logic behind this is understandable: the faster a drug provides relief, the higher the repeat purchase or prescription. That is because the increased speed of symptom relief allows patients to return to their usual quality of life sooner.

    BioNxt is dedicated to helping patients regain their quality of life. Its solutions at the point of care offer rapid diagnosis, associated rapid relief and gentle drug delivery. BioNxt sees itself as an accelerator, and its successes to date prove it right: the faster patients experience relief, the greater the appreciation of the successes BioNxt provides through its research and work.

    Bayer - New results in the fight against prostate cancer

    In recent decades, the number of new cases of prostate cancer within the group of adult men has increased worldwide. In Europe, approximately 2.6 million new cases are diagnosed each year.

    Signs of prostate cancer include difficulty urinating, blood in the urine or seminal fluid, pain during ejaculation and in the back, pelvis or hips, and potency problems. These warning signs should be clarified immediately by a doctor so that a possible serious illness can be recognised and treated at an early stage.

    Bayer is strongly committed to advancing oncology research and development, focusing on three scientific areas that have the potential to address the unmet needs of cancer patients.

    These include:

    1. next generation immuno-oncology
    2. targeted radionuclide therapies
    3. molecular precision oncology

    Important data from all three areas will be presented at this year's conference to demonstrate Bayer's progress and achievements in oncology research. Precision oncology will be presented, underscoring Bayer's commitment to advancing the future of cancer treatment.

    Bayer is committed to researching its prostate cancer drug, darolutamide, to help many men affected by the disease. Bayer remains committed to advancing the research and development of darolutamide and other innovative drugs to fight prostate cancer.

    Morphosys - Achieves first results in the fight against bone marrow cancer

    Myelofibrosis is a malignant and rare disease of the bone marrow that occurs in the form of primary myelofibrosis (PMF) or as a secondary consequence of another myeloproliferative disease. In Germany, about 0.5 to 1.5 out of 100,000 people develop this type of cancer every year. That corresponds to approximately 1,000 new cases per year, with the average age of those affected being around 65 years.

    Men are affected slightly more often than women, accounting for 65% of cases. Although myelofibrosis is not inherited according to current knowledge, there are familial clusters. Morphosys AG completed enrolment in the study investigating its therapeutic in the fight against this insidious disease at the beginning of April. This is a Phase III study investigating the efficacy and safety of pelabresib, a BET inhibitor, in combination with ruxolitinib in patients with myelofibrosis who have not previously been treated with a JAK inhibitor.

    Combination therapy is being studied in comparison to ruxolitinib alone. Top-line data will be published earlier than expected in late 2023, which is positive for the stock. Incyte (INCY) is currently in trials of its own BET inhibitor, which can be used in combination with Jakafi. The product is undergoing Phase I trials and being tested for efficacy. In addition, the Company has another product in Phase III, the PI3K inhibitor parsaclisib. This is being studied as a combination therapy with ruxolitinib in patients who do not respond adequately to ruxolitinib. Results are due to be published in 2023. However, class-wide safety overhang is a major problem, as has already been observed with Incyte. The Company had to withdraw the NDA for marginal zone lymphoma, follicular lymphoma and mantle cell lymphoma.

    For patients who have already been diagnosed, speed is everything. That is where BioNxt Solutions comes in, with its novel coating technology that enables conventional agents to relieve disease symptoms more quickly. For pharma and doctors, this is one of the main arguments for helping sufferers. Anyone who has ever taken a drug in the hope that it would work quickly - and it didn't - appreciates the speed of drug release. On the other hand, more and more men should take a closer look at the shares of Bayer. The increase in prostate cancer seems concerning. It is all the more valuable that a company like Bayer is focusing on where a man's most precious asset is permanently at risk, and non-treatment could end fatally. Morphosys is also joining the fight against cancer, in this case, bone marrow cancer. Here, men are also more often affected than women. Investors should carefully consider who they are backing with their investment.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author

    Related comments:

    Commented by Armin Schulz on April 15th, 2024 | 06:15 CEST

    Varta, Carbon Done Right Developments, Bayer - Buy when the cannons are firing?

    • Sustainability
    • renewableenergies
    • Pharma

    The stock market is a fascinating place where investors have to weigh up their opportunities and risks. An often-quoted stock market adage is: "Buy when the cannons are firing". The idea behind this is that one can find opportunities for lucrative investments in times of crisis when market sentiment is particularly poor. Warren Buffett also supports the idea of buying securities or companies at times when the majority of investors are pessimistic, causing prices to fall below the actual value of the investments. He said: "Be greedy when others are fearful and be fearful when others are greedy." We have selected three candidates who have recently lost ground and shed light on whether an investment is worthwhile.


    Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

    AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

    • Biotechnology
    • Pharma
    • AI

    Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?


    Commented by Fabian Lorenz on April 10th, 2024 | 07:00 CEST

    BASF and Cardiol Therapeutics recommended to buy! TUI share with momentum!

    • Biotechnology
    • Cancer
    • travel
    • chemicals

    BASF shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the share did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see little potential for further price increases. The situation is different for the biotech company Cardiol Therapeutics. The analysts at Canaccord believe that the shares of the specialist in cardiovascular diseases could perform by around 200%. Financing is secured until 2026, and important study data is due in the current quarter. The TUI share has been on a roll for several months now. Will the share continue to rise with the increase in temperatures? Management is certainly optimistic about the future.